BLU Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BELLUS Health Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ:BLU) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BELLUS securities between September 5, 2019 and July 5, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.comblu

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose that: Specifically, the complaint alleges that BELLUS (1) deceived the investing public about its business, operations, drug products, drug product development, competition, and present and future business prospects; (2) facilitated the Company's September 2019 public offering ("Offering"); (3) created artificial demand for the BELLUS common shares sold in the Offering; (4) enabled the Company to receive approximately $70 million in net proceeds from the sale of BELLUS common stock in the Offering; and (5) caused Plaintiff and the Class to purchase BELLUS publicly traded common stock at artificially inflated prices.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/blu or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in BELLUS you have until May 17, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/635908/BLU-Shareholder-Alert-Bronstein-Gewirtz-Grossman-LLC-Notifies-BELLUS-Health-Inc-Investors-of-Class-Action-and-Encourages-Shareholders-to-Contact-the-Firm

News Provided by ACCESSWIRE IA via QuoteMedia

The Conversation (0)

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024 to all stockholders of record as of the close of business on May 17, 2024 .

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 44 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday March 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, and Paul Burton senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Half Yearly Report and Accounts

BPH Global Ltd (ASX: BP8) (Company) is pleased to present its Half Year Report.


Keep reading...Show less

Latest Press Releases

Related News

×